Filtered By:
Drug: Gilenya

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 88 results found since Jan 2013.

S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen ‐glucose deprivation‐induced neuroinflammation via inhibiting TLR2/4‐NFκB signalling
This study was intended to investigate the mechanisms of phosphorylated FTY720 (pFTY720), which was the principle active molecule in regulating astrocyte‐mediated inflammatory responses induced by oxygen‐glucose deprivation (OGD). Results demonstrated that pFTY720 could protect astrocytes against OGD‐induced injury and inflammatory responses. It significantly decreased pro‐inflammatory cytokines, including high mobility group box 1 (HMGB1) and tumour necrosis factor‐α (TNF‐α). Further, studies displayed that pFTY720 could prevent up‐regulation of Toll‐like receptor 2 (TLR2), phosphorylation of phosphoinos...
Source: Journal of Cellular and Molecular Medicine - March 13, 2018 Category: Molecular Biology Authors: Yin ‐Feng Dong, Ruo‐Bing Guo, Juan Ji, Lu‐Lu Cao, Ling Zhang, Zheng‐Zhen Chen, Ji‐Ye Huang, Jin Wu, Jun Lu, Xiu‐Lan Sun Tags: ORIGINAL ARTICLE Source Type: research

S1PR3 is essential for phosphorylated fingolimod to protect astrocytes against oxygen-glucose deprivation-induced neuroinflammation via inhibiting TLR2/4-NF κB signalling.
This study was intended to investigate the mechanisms of phosphorylated FTY720 (pFTY720), which was the principle active molecule in regulating astrocyte-mediated inflammatory responses induced by oxygen-glucose deprivation (OGD). Results demonstrated that pFTY720 could protect astrocytes against OGD-induced injury and inflammatory responses. It significantly decreased pro-inflammatory cytokines, including high mobility group box 1 (HMGB1) and tumour necrosis factor-α (TNF-α). Further, studies displayed that pFTY720 could prevent up-regulation of Toll-like receptor 2 (TLR2), phosphorylation of phosphoinositide 3-kinase (...
Source: J Cell Mol Med - March 13, 2018 Category: Molecular Biology Authors: Dong YF, Guo RB, Ji J, Cao LL, Zhang L, Chen ZZ, Huang JY, Wu J, Lu J, Sun XL Tags: J Cell Mol Med Source Type: research

Treatment with FTY720 has no beneficial effects on short-term outcome in an experimental model of intracerebral hemorrhage
ConclusionsOur results suggest that FTY720 has no beneficial effects in the acute phase of experimental ICH.
Source: Experimental and Translational Stroke Medicine - February 18, 2016 Category: Neurology Source Type: research

Fingolimod Enhances the Efficacy of Delayed Alteplase Administration in Acute Ischemic Stroke by Promoting Anterograde Reperfusion and Retrograde Collateral Flow
Annals of Neurology,Volume 0, Issue ja, -Not available-.
Source: Annals of Neurology - October 8, 2018 Category: Neurology Authors: De ‐Cai Tian, Kaibin Shi, Zilong Zhu, Jia Yao, Xiaoxia Yang, Lei Su, Sheng Zhang, Meixia Zhang, Rayna J. Gonzales, Qiang Liu, DeRen Huang, Michael F. Waters, Kevin N. Sheth, Andrew F. Ducruet, Ying Fu, Min Lou, Fu‐Dong Shi Source Type: research

Repurposing multiple sclerosis drugs: a review of studies in other neurological and psychiatric conditions.
Abstract Treatment options for multiple sclerosis (MS) have improved in the past 20 years, with new oral disease-modifying drugs and monoclonal antibodies becoming available. The success seen with these drugs in MS, and their various mechanisms of action, has led to them being investigated in other neurological and psychiatric disorders. This review article summarises the ongoing and completed studies of MS drugs in neurological and psychiatric conditions other than MS. The most promising results are for interferon beta in human T cell leukaemia virus 1 associated myelopathy/tropical spastic paraparesis and glioma...
Source: Drug Discovery Today - May 13, 2019 Category: Drugs & Pharmacology Authors: Rommer PS, Sellner J Tags: Drug Discov Today Source Type: research

Efficacy of the sphingosine-1-phosphate receptor agonist fingolimod in animal models of stroke: an updated meta-analysis
.
Source: International Journal of Neuroscience - March 8, 2020 Category: Neuroscience Authors: Chun Dang Yaoheng Lu Qian Li Chunyang Wang Xiaofeng Ma Source Type: research

18F-FAC PET Visualizes Brain-Infiltrating Leukocytes in a Mouse Model of Multiple Sclerosis
Conclusion: 18F-FAC PET can visualize brain-infiltrating leukocytes in a mouse MS model and can monitor the response of these cells to an immunomodulatory drug. Translating this strategy into humans will require exploring additional radiotracers.
Source: Journal of Nuclear Medicine - April 30, 2020 Category: Nuclear Medicine Authors: Chen, B. Y., Ghezzi, C., Villegas, B., Quon, A., Radu, C. G., Witte, O. N., Clark, P. M. Tags: Basic Source Type: research

Neuroinflammation in hemorrhagic transformation after tissue plasminogen activator thrombolysis: Potential mechanisms, targets, therapeutic drugs and biomarkers.
Abstract Hemorrhagic transformation (HT) is a common and serious complication following ischemic stroke, especially after tissue plasminogen activator (t-PA) thrombolysis, which is associated with increased mortality and disability. Due to the unknown mechanisms and targets of HT, there are no effective therapeutic drugs to decrease the incidence of HT. In recent years, many studies have found that neuroinflammation is closely related to the occurrence and development of HT after t-PA thrombolysis, including glial cell activation in the brain, peripheral inflammatory cell infiltration and the release of inflammato...
Source: International Immunopharmacology - December 6, 2020 Category: Allergy & Immunology Authors: Ma G, Pan Z, Kong L, Du G Tags: Int Immunopharmacol Source Type: research

Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage
Intracerebral haemorrhage (ICH) has no specific treatment, but accounts for up to 15% of all strokes and has the highest mortality. Fingolimod (FTY720) is an immunomodulator approved for the management of multiple sclerosis, with abundant evidence of efficacy in experimental ischemic stroke, and more limited evidence in experimental ICH. The goal of this study was to confirm the efficacy of fingolimod in experimental ICH using rigorous and statistically well-powered studies. ICH was induced in C57BL/6JOlaHsd male and female mice by intrastriatal bacterial collagenase injection. Fingolimod (0.5 mg/kg) or saline was adminis...
Source: Frontiers in Pharmacology - January 8, 2021 Category: Drugs & Pharmacology Source Type: research

The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia
The role of the immune system in stroke is well-recognised. Fingolimod, an immunomodulatory agent licensed for the management of relapsing-remitting multiple sclerosis, has been shown to provide benefit in rod...
Source: Journal of Neuroinflammation - January 30, 2021 Category: Neurology Authors: Kyle Malone, Andrea C. Diaz Diaz, Jennifer A. Shearer, Anne C. Moore and Christian Waeber Tags: Research Source Type: research

Sphingosine-1-phosphate and Sphingosine-1-phosphate receptors in the cardiovascular system: pharmacology and clinical implications
Adv Pharmacol. 2022;94:95-139. doi: 10.1016/bs.apha.2022.02.001. Epub 2022 Mar 30.ABSTRACTSphingosine-1-phosphate (S1P) is a lipid that binds and activates five distinct receptor subtypes, S1P1, S1P2, S1P3, S1P4, S1P5, widely expressed in different cells, tissues and organs. In the cardiovascular system these receptors have been extensively studied, but no drug acting on them has been approved so far for treating cardiovascular diseases. In contrast, a number of S1P receptor agonists are approved as immunomodulators, mainly for multiple sclerosis, because of their action on lymphocyte trafficking. This chapter summarizes t...
Source: Adv Data - June 6, 2022 Category: Epidemiology Authors: Simona Federica Spampinato Maria Angela Sortino Salvatore Salomone Source Type: research